The company pays a $1.12 Dividend, which at these levels is over 5%. Below $20 makes BMY ripe for a takeover.
BMS Buys Celgene In one of the biggest pharma takeovers ever, Bristol-Myers Squibb is paying $90 billion for Celgene, a company specializing in leukemia treatment. BMS thus far has a focus on solid tumors. Celgene CEO Mark Alles said the two companies had "complementary assets in different diseases and here we get to build on the scientific capabilities of both in a way that could not happen without this deal." Wall Street Journal
On Thursday, 01/04/19, Celgene (CELG) appreciated 20.7% after agreeing to be acquired by Bristol-Myers Squibb (BMY).